Last updated: February 3, 2026
Summary
OMNIPAQUE 180 (Iohexol), a contrast agent developed by GE Healthcare, is used for diagnostic imaging, primarily in computed tomography (CT) scans. As an iodine-based contrast medium, OMNIPAQUE 180 is integral to radiology procedures. Its market outlook is influenced by evolving healthcare technology, regulatory environments, competitive landscape, and global demand for diagnostic imaging. This analysis delineates the current market positioning, growth drivers, competitive risks, and financial expectations pertinent to IDA investors and pharmaceutical stakeholders aiming to assess OMNIPAQUE 180’s long-term viability.
What are the Market Dynamics for OMNIPAQUE 180?
1. Market Size and Regional Distribution
| Region |
Market Share (2022) |
Key Factors |
Growth Rate (CAGR 2023–2028) |
| North America |
~40% |
Extensive imaging infrastructure, high healthcare spending |
4.2% |
| Europe |
~30% |
Aging population, regulatory approvals |
3.8% |
| Asia-Pacific |
~20% |
Rapid urbanization, expanding healthcare systems |
7.0% |
| Rest of World (RoW) |
~10% |
Emerging markets, increasing diagnostic needs |
7.5% |
The global contrast media market was valued at approximately $4.4 billion in 2022 and projected to reach $6.9 billion by 2028, growing at a CAGR of 8.2% (Grand View Research).
2. Drivers of Market Growth
| Driver |
Impact and Evidence |
| Increasing Diagnostic Imaging Procedures |
Growing aging populations and prevalent chronic diseases escalate demand for CT scans, bolstering contrast agent utilization. |
| Advancements in Imaging Technology |
Higher-resolution imaging facilitates broader application, increasing contrast agent requirements. |
| Regulatory Approvals for New Formulations |
Expansion of indications and formulations (e.g., low-osmolar agents) improve market size. |
| Market Penetration in Emerging Economies |
Rising healthcare infrastructure promotes adoption, especially in Asia-Pacific. |
3. Competitive Landscape
| Major Competitors |
Market Share (2022) |
Notable Attributes |
| GE Healthcare (OMNIPAQUE 180) |
Leading (~50%) |
Established brand, extensive distribution network |
| Bracco Imaging (XENETIX) |
~15% |
Focus on innovation, expanding into emerging markets |
| Guerbet (Lipiodol, Visipaque) |
~10% |
Diversified contrast portfolio |
| Other regional/imported brands |
~25% |
Variable quality, price-sensitive markets |
Price Points & Product Differentiation:
OMNIPAQUE 180's average list price varies regionally, with North America averaging $15–20 per dose, influenced by healthcare reimbursement policies and competitive pricing strategies.
What is the Financial Trajectory of OMNIPAQUE 180?
1. Revenue Projections (2023–2030)
| Year |
Estimated Global Revenue (USD Millions) |
Assumptions |
| 2023 |
$1,100 |
Continued volume growth, moderate price stability |
| 2025 |
$1,500 |
Market expansion, new regional approvals |
| 2028 |
$2,100 |
Penetration in emerging markets, broader indications |
| 2030 |
$2,600 |
Market maturity in core regions, sustained growth |
Compound Annual Growth Rate (CAGR):
Projected at 9.1% from 2023–2030, influenced by shifts towards newer contrast agents, generics, and market expansion.
2. Cost Structure and Profitability
| Cost Element |
Approximate % of Revenue |
Notes |
| Manufacturing & Raw Materials |
25–30% |
Procurement of iodine, gelatin, packaging |
| R&D |
8–12% |
Innovation, formulation improvements, new indications |
| Regulatory & Compliance |
5–8% |
Approvals, post-market surveillance |
| Marketing & Distribution |
10–15% |
Global marketing, training, supply chain logistics |
| Gross Margin |
65–70% |
Reflects premium pricing and cost efficiency |
3. Regulatory Factors Impacting Financials
| Regulatory Component |
Effect |
Status/Trend |
| FDA & EMA Approvals |
Ensures market continuity, new indications expansion |
Continued approvals |
| Post-market Surveillance & Safety |
Drives costs, impacts reimbursement decisions |
Increasing scrutiny |
| Patent & Exclusivity |
Patent expiry impacts pricing, generic entry expected in 2026 |
Patent lapse anticipated |
Comparative Analysis: OMNIPAQUE 180 Versus Competitors
| Attribute |
OMNIPAQUE 180 |
XENETIX (Bracco) |
Visipaque (Guerbet) |
| Active Ingredient |
Iohexol |
Iodixanol (Iso-Osmolar) |
Iodixanol |
| Osmolality |
Low (180 mg Iodine/mL) |
Iso-osmolar |
Iso-osmolar |
| Pricing |
Premium (USD 15–20/dose) |
Similar or slightly lower |
Similar |
| Indications |
CT, angiography |
CT, angiography |
CT, angiography |
| Regulatory Status |
Widely approved |
Approved globally |
Approved globally |
| Market Share |
~50% |
~15% |
~10% |
What Are the Key Investment Risks and Opportunities?
Risks
| Risk Element |
Impact |
Mitigation Strategies |
| Patent Expiry |
Generic competition reduces margins |
Diversify portfolio, innovate formulation |
| Regulatory Delays or Restrictions |
Market access constraints |
Engage proactively with regulators |
| Pricing Pressures from GPOs/Ethics |
Margins erode due to negotiations |
Cost optimization, value-based marketing |
| Market Saturation in Developed Regions |
Slower growth in North America, Europe |
Focus on emerging markets, new indications |
Opportunities
| Opportunity |
Expected Impact |
Strategic Actions |
| Adoption of Low-Osmolar Contrast Agents |
Enhanced safety profile, higher demand |
Promote OMNIPAQUE 180 advantages |
| Expansion into Emerging Markets |
Higher growth potential |
Local partnerships, regulatory approval efforts |
| Broaden Indications and Usage |
New revenue streams |
Clinical trials, regulatory submissions |
Deep Dive: Future Trends and Policy Impacts
| Trend / Policy |
Effect |
Outlook |
| Value-based healthcare policies |
Emphasize cost-effectiveness of diagnostic agents |
Increased demand for efficient contrast media |
| Increase in Diagnostic Imaging Use |
Greater volume of contrast media applications |
Positive for OMNIPAQUE sales if maintained |
| Environmental Regulations on Fluorosolvants |
Potential regulation of manufacturing processes |
Need for sustainable production practices |
| Digitalization and AI in Imaging |
Improved diagnosis precision, potentially higher contrast agent requirements |
Drive innovation in contrast media formulations |
Conclusion
OMNIPAQUE 180 occupies a resilient position within the global contrast media market, with an established brand presence, a broad regulatory footprint, and steady demand driven by expanding diagnostic procedures. Its financial trajectory points toward sustained growth trajectories, especially in emerging markets, with an approximate CAGR exceeding 9%. However, patent expirations, pricing pressures, and regulatory challenges pose risks that require strategic management.
Investment opportunities exist through market expansion, product innovation, and geographical penetration. Conversely, cost controls and patent protections are critical to preserving margins and market share.
Key Takeaways
- The global contrast media market is robust, projected to grow at an 8.2% CAGR, with OMNIPAQUE 180 as a prominent player.
- Asia-Pacific and emerging markets exhibit the highest growth potential, with CAGR up to 7.5%.
- Revenue is expected to reach approximately $2.6 billion globally by 2030, driven by increased imaging procedures and new indications.
- Competitive risks include patent expirations (anticipated around 2026 in key regions) and price competition.
- Strategic focus should be on product innovation, regional expansion, and maintaining regulatory agility to sustain financial growth.
FAQs
Q1: When is OMNIPAQUE 180 expected to lose its patent exclusivity?
Patent protections for OMNIPAQUE 180 are expected to lapse around 2026 in several key markets, opening opportunities for generics and biosimilars.
Q2: How does OMNIPAQUE 180 compare cost-wise to newer contrast agents?
While premium-priced (~$15–20/dose), OMNIPAQUE 180 offers a proven safety and efficacy profile. Generic entries post-patent expiry could reduce costs significantly.
Q3: What regulatory hurdles could impact the growth of OMNIPAQUE 180?
Post-market safety regulations, approval for new indications, and environmental standards remain pivotal. Delays can impact market expansion timelines.
Q4: Which regions offer the highest growth for contrast media?
Asia-Pacific and Latin America are poised for rapid growth, driven by healthcare infrastructure development and aging populations.
Q5: What diversification strategies can improve long-term investment viability?
Development of new formulations (e.g., low-osmolar, microbubble contrast agents), expanding into molecular imaging, and strategic alliances can mitigate risks.
References
[1] Grand View Research. Contrast Media Market Size, Share & Trends Analysis Report, 2022.
[2] GE Healthcare. OMNIPAQUE Product Literature, 2022.
[3] MarketsandMarkets. Diagnostic Imaging Markets - Industry Trends & Forecasts, 2023.
[4] FDA Regulations on Contrast Media, 2022.
[5] Bracco Imaging. XENETIX Product Data Sheet, 2022.
